Clinical trials
Community-Acquired Pneumonia trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Unknown status | 6 |
| Terminated | 4 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biotest | 4 |
| Hospital Universitari de Bellvitge | 3 |
| Pfizer | 3 |
| Forest Laboratories | 2 |
| Aptarion Biotech AG | 1 |
| AstraZeneca | 1 |
| Bayer | 1 |
| David Garcia Cinca | 1 |
| Enlivex Therapeutics Ltd. | 1 |
| Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Community-Acquired Pneumonia | 32 |
| Pneumonia | 8 |
| COVID-19 | 4 |
| Pneumonia, Bacterial | 3 |
| Infections | 2 |
| Respiratory Distress Syndrome | 2 |
| Respiratory Tract Infections | 2 |
| Cholecystitis, Acute | 1 |
| Communicable Diseases | 1 |
| Community-Acquired Infections | 1 |
Trials
Showing 26 to 32 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.